Effects of interferon-alpha on macrophage activation in patients with ovarian carcinoma and cervical dysplasia.
Patients with progressive ovarian carcinoma and patients with dysplasia of the uterine cervix were studied in order to compare clinical efficacy, hematological toxicity and effects on macrophage activation of administered interferon-alpha for both patient groups. One of three patients with ovarian carcinoma showed a minor response. Four of six patients with cervical dysplasia had slight improvements of PAP-smears. Moderate hematological toxicity was observed in the former patient group while side effects were much more pronounced in the latter patients group. However, changes of hematological parameters were not statistically different. Interestingly, the administered interferon-alpha caused the same activation of macrophages in both patients groups as indicated by raised neopterin levels. This activation does not result in clinical improvement but appears to play a role for the hematological toxicity observed during therapy of patients with ovarian carcinoma. It has been suggested that suppression of hematopoiesis is mediated by interferon-gamma. The present neopterin data propose that this lymphokine is continuously produced through influence of the tumor and enhanced by interferon-alpha.
Fuith
L C
LC
Department of Obstetrics and Gynecology, University of Innsbruk, Austria.
Fuchs
D
D
Hausen
A
A
Hetzel
H
H
Reibnegger
G
G
Werner
E R
ER
Wachter
H
H
D000328:Adult; D001708:Biopterins / Q000031:analogs & derivatives / Q000652:urine; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007370:Interferon Type I / Q000627:therapeutic use*; D008262:Macrophage Activation; D008875:Middle Aged; D019798:Neopterin; D010051:Ovarian Neoplasms / Q000276:immunology / Q000628:therapy* / Q000652:urine; D002578:Uterine Cervical Dysplasia / Q000276:immunology / Q000628:therapy* / Q000652:urine
D007370:Interferon Type I; D001708:Biopterins; D019798:Neopterin